Alan Weichselbaum
Patrimonio netto: 851 900 $ in data 31/05/2026
Patrimonio netto: 851 900 $ in data 31/05/2026
Alan Weichselbaum is the founder of The Wexus Group LLC, founded in 2011.
Current jobs include Chairman & Managing Member at Gimmel Partners LP since 2012, Director at Young Israel of Lawrence-Cedarhurst, Director at Tony Power, and Director at FinWise Bancorp since 2022.
Former jobs include CEO, Acting Chief Financial Officer & CAO at Jesup & Lamont, Inc. from 2009 to 2012; Director at Rock Creek Pharmaceuticals, Inc. in 2010; Director at FinWise Bank; Director at FinWise Bancorp from 2015 to 2021; Analyst at Fulcrum Global Partners LLC in 2004; Manager-Financial Planning & Analysis at Philip Morris Capital Corp.; Chief Financial Officer & Treasurer at MIRA Pharmaceuticals, Inc. from 2025 to 2026; and Chief Financial Officer at Telomir Pharmaceuticals, Inc. from 2025 to 2026.
Education includes an undergraduate degree from Queens College in 1986 and an MBA from New York University in 1999.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
FINWISE BANCORP 0,43% | 21/04/2026 | 59.242 ( 0,43% ) | 851 900 $ | 31/05/2026 |
| 15/05/2025 | 0 ( -.--% ) | - $ | 31/05/2026 | |
| 15/05/2025 | 0 ( -.--% ) | - $ | 31/05/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| FINWISE BANCORP | Direttore/Membro del Consiglio | 01/10/2022 |
Gimmel Partners LP | Presidente | 01/10/2005 |
Young Israel of Lawrence-Cedarhurst | Direttore/Membro del Consiglio | - |
Tony Power | Direttore/Membro del Consiglio | - |
| Società | Posizione | Fine |
|---|---|---|
| MIRA PHARMACEUTICALS, INC. | Direttore Finanziario/CFO | 06/06/2026 |
| TELOMIR PHARMACEUTICALS, INC. | Direttore Finanziario/CFO | 06/06/2026 |
| FINWISE BANCORP | Direttore/Membro del Consiglio | 07/05/2021 |
FinWise Bank
FinWise Bank Regional BanksFinance Provides state chartered commercial banking services | Direttore/Membro del Consiglio | 07/05/2021 |
| ROCK CREEK PHARMACEUTICALS, INC. | Direttore/Membro del Consiglio | 22/10/2010 |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 14 |
|---|---|
Rock Creek Pharmaceuticals, Inc.
Rock Creek Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures a variety of pharmaceutical products | Health Technology |
Fulcrum Global Partners LLC
Fulcrum Global Partners LLC Investment Banks/BrokersFinance Provides securities research analysis and trade execution services | Finance |
Queens College
Queens College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
New York University
New York University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Philip Morris Capital Corp.
Philip Morris Capital Corp. Finance/Rental/LeasingFinance Functions as a financing subsidiary/special purpose entity | Finance |
Gimmel Partners LP | |
Young Israel of Lawrence-Cedarhurst | Commercial Services |
Tony Power | |
Jesup & Lamont, Inc.
Jesup & Lamont, Inc. Investment Banks/BrokersFinance Provides securities brokerage, asset management and market services | Finance |
FinWise Bank
FinWise Bank Regional BanksFinance Provides state chartered commercial banking services | Finance |
FinWise Bancorp
FinWise Bancorp Regional BanksFinance Operates as a bank holding company whose subsidiary provides banking services | Finance |
MIRA Pharmaceuticals, Inc.
MIRA Pharmaceuticals, Inc. Pharmaceuticals: OtherHealth Technology Develops and sells new molecular synthetic THC for the treatment of adult patients with anxiety and cognitive decline | Health Technology |
THE WEXUS GROUP LLC
THE WEXUS GROUP LLC Miscellaneous Commercial ServicesCommercial Services Operates as a a financial firm that provides accounting, vendor management, bookkeeping, marketing strategies and consulting services | Commercial Services |
Telomir Pharmaceuticals, Inc.
Telomir Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops a novel small molecule as the first regulator of telomere length and genomic stability | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale